Erythroid promoter confines FGF2 expression to the marrow after hematopoietic stem cell gene therapy and leads to enhanced endosteal bone formation

TY - JOUR

T1 - Erythroid promoter confines FGF2 expression to the marrow after hematopoietic stem cell gene therapy and leads to enhanced endosteal bone formation

AU - Meng, Xianmei

AU - Baylink, David J.

AU - Sheng, Matilda

AU - Wang, Hongjie

AU - Gridley, Daila S.

AU - Lau, K. H.William

AU - Zhang, Xiao Bing

N1 - Fibroblast growth factor-2 (FGF2) has been demonstrated to be a promising osteogenic factor for treating osteoporosis. Our earlier study shows that transplantation of mouse Sca-1+ hematopoietic stem/progenitor cells that are engineered to express a modified FGF2 leads to considerable endosteal/trabecular bone formation, but it also induces adverse effects like hypocalemia and osteomalacia.

PY - 2012/5/18

Y1 - 2012/5/18

UR - https://www.scopus.com/pages/publications/84862075829

UR - https://www.scopus.com/pages/publications/84862075829#tab=citedBy

U2 - 10.1371/journal.pone.0037569

DO - 10.1371/journal.pone.0037569

M3 - Article

C2 - 22629419

SN - 1932-6203

VL - 7

JO - PLoS ONE

JF - PLoS ONE

IS - 5

M1 - e37569

ER -